Olema Pharmaceuticals (OLMA) Cash from Financing Activities (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Cash from Financing Activities data on file, last reported at $45.7 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $45.7 million, up 20487.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $256.8 million (down 1.32% YoY), and the FY2025 annual result was $211.3 million, down 21.4% from the prior year.
• Cash from Financing Activities eased to $45.7 million in Q1 2026 per OLMA's latest filing, from $213.6 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $244.3 million in Q4 2024 and troughed at -$2.5 million in Q2 2025.
• A 5-year average of $38.8 million and a median of $273000.0 in 2022 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities jumped 123134.91% in 2023, then sank 116.14% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at $273000.0 in 2022, then soared by 91.58% to $523000.0 in 2023, then surged by 46611.28% to $244.3 million in 2024, then retreated by 12.59% to $213.6 million in 2025, then plunged by 78.6% to $45.7 million in 2026.
• Business Quant data shows OLMA's Cash from Financing Activities at $45.7 million in Q1 2026, $213.6 million in Q4 2025, and $41000.0 in Q3 2025.